StockMarketWire.com - Bio-marker group Oxford BioDynamics noted that its technology had been used in a medical study, the results of which were published in the peer-reviewed journal EBioMedicine.
In the study, the company's EpiSwitch platform was used to compare the genomic architecture of healthy and ayotrophic lateral sclerosis patient samples to discover an epigenetic bio-marker.
The study successfully yielded a distinct bio-marker that was diagnostic for the condition, demonstrating a highly-promising, potential new approach to the diagnosis of the disease, Oxford BioDynamics said.
At 9:46am: [LON:OBD] Oxford Biodynamics Plc share price was 0p at 212p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.